



Supplementary information, Fig. S4. Identification of OLFR796 as a receptor of famsin.

a Coomassie staining showing SDS-PAGE separation of GST, GST-famsin, His-ProS2 and His-ProS2-famsin purified from *E. coli*. **b** Effect of famsin-Flag-His purified from Hi-5 cells and GST-famsin purified from *E. coli* on relative *G6pc* mRNA levels in mouse primary hepatocytes in the presence or absence of SCH-202676 (SCH, 10 μ M). Data are shown as mean \pm s.e.m. Comparison of different groups was carried out using two-way ANOVA followed by Tukey's test. *** $p < 0.001$. $n = 6$. **c-d** Binding assay on HEK293T cells evaluated by immunostaining (**c**) or flow cytometry (**d**). 100 nM GST or GST-famsin was incubated with HEK293T cells. For competition binding, cells were pretreated with 5 μ M His-ProS2 or His-ProS2-famsin for 30 min. Scale bars, 10 μ m. **e** siRNA library screening for GPCRs that modulate the binding of GST-famsin in HEK293T cells. **f** Correlation between the two replicates of the primary siRNA screen. Results are shown as fold change (on a \log_2 scale) of famsin binding in siRNA knockdown cells relative to cells transfected with non-targeting siRNA. Spearman's rank correlation coefficient ($r = 0.94$) between the two replicates is shown. **g** Alignment of human OR10P1 and mouse OLFR796. The predicted transmembrane domains (TM) are surrounded by the blue boxes. **h** Effect of *OR10P1* knockdown or addition of OLFR796-Flag on GST-famsin binding (top panel) and mRNA level of *OR10P1* or *Olfir796* (bottom panel) in HEK293T cells. A mixture of siRNAs (5'-CGATCATCCCGCACTTCT-3', 5'-CCTCTTACATCCGCATCCT-3' and 5'-TGATGACAGCCACCATAGT-3') that target *OR10P1* was used in this assay. NT, non-target RNAi. Scale bars, 10 μ m. Data are shown as mean \pm s.e.m. Comparison of different groups was carried out using one-way ANOVA followed by Tukey's test. ** $p < 0.01$. $n = 3$. **i** qPCR results showing relative mRNA levels of *OR10P1* in human tissues. Data are shown as mean \pm s.e.m. $n = 4$. **j** Generation of *Olfir796*^{-/-} mice by CRISPR-Cas9. A deletion of 47 bp was introduced in exon 2 of the *Olfir796* gene. **k** The partial N-terminal sequence of WT OLFR796 and the full sequence of the truncated OLFR796 protein product in *Olfir796*^{-/-} mice are shown. The frame-shifted amino acids of OLFR796 generated by the deletion in *Olfir796*^{-/-} mice are shown in red. **l** PCR analysis showing *Olfir796* fragments generated from *Olfir796*^{+/+} and *Olfir796*^{-/-} mice. **m** Relative mRNA levels of *Olfir796* in the liver or skeletal muscle extracts from 8-10-week-old male *Olfir796*^{+/+} and *Olfir796*^{-/-} mice. Data are shown as mean \pm s.e.m. Comparison of different groups was carried out using unpaired two-tailed Student's *t*-test. *** $p < 0.001$. $n = 5$ mice. **n** A representative chromatogram from size exclusion chromatography of OLFR796-Flag-His or its mutant (R187D, R195D and E197A) purified from Hi-5 cells. microAU, micro-ultraviolet absorbance at 280 nm. **o** Silver staining showing purified OLFR796-Flag-His and its mutant (R187D, R195D and E197A) separated by SDS-PAGE. **p** Similar cellular localization of WT OLFR796 and its mutant (R187D, R195D and E197A) evaluated by anti-FLAG staining in Cos7 cells. Scale bars, 10 μ m. **q** qPCR results showing relative expression of *Olfir796* in *Olfir796*^{+/+} or *Olfir796*^{-/-} primary hepatocytes with or without overexpression of *Olfir796* in the presence or absence of famsin (30 nM). Data are shown as mean \pm s.e.m. Comparison of different groups was carried out using two-way ANOVA followed by Tukey's test. *** $p < 0.001$. NS, no statistical significance. $n = 3$. **r** Relative *G6pc* mRNA levels following treatment with different doses of famsin in mouse primary hepatocytes. Data are shown as mean \pm s.e.m. $n = 6$. **s** Effect of famsin (30 nM) on glucose output in mouse primary hepatocytes. Data are shown as mean \pm s.e.m. Comparison of different groups was carried out using unpaired two-tailed Student's *t*-test. *** $p < 0.001$. $n = 6$. **t** Effect of 10 min treatment with famsin (30 nM) or glucagon (100 nM) on cellular cAMP levels in mouse primary hepatocytes. Data are shown as mean \pm s.e.m. Comparison of different groups was carried out using one-way ANOVA followed by Tukey's test. ** $p < 0.01$. NS, no statistical significance. $n = 3$. **u** qPCR results showing relative expression of *Gnal* in the liver or OB extracts from 8-10-week-old male mice. Data are shown as mean \pm s.e.m. Comparison of different groups was carried out using unpaired two-tailed Student's *t*-test. *** $p < 0.001$. $n = 5$ mice. **v** Immunoblot showing relative expression of GNAL in the liver or OB extracts from 8-10-week-old male mice. **w** Co-immunoprecipitation showing the association of OLFR796-HA with GNAQ-Flag or GNAL-Flag in HEK293T cells treated with or without famsin (30 nM) for 10 min. **x-y** Effect of famsin on cAMP levels of liver (**x**) or OB (**y**) extracts from 8-10-week-old *Olfir796*^{+/+} and *Olfir796*^{-/-} male mice. Data are shown as mean \pm s.e.m. Comparison of different groups was carried out using two-way ANOVA followed by Tukey's test. *** $p < 0.001$. NS, no statistical significance. $n = 5$ mice.